ABBV-701
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
(clinicaltrials.gov)
- P1 | N=58 | Recruiting | Sponsor: AbbVie
New P1 trial
1 to 1
Of
1
Go to page
1